Please login to the form below

Not currently logged in
Email:
Password:

Viaskin Peanut

This page shows the latest Viaskin Peanut news and features for those working in and with pharma, biotech and healthcare.

FDA knocks back DBV’s peanut allergy therapy once again

FDA knocks back DBV’s peanut allergy therapy once again

drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Analysts at Baird have suggested that with a weaker clinical

Latest news

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... California biotech Aimmune has been in a race to

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    Peanut allergies are the leading cause of death from food-induced allergic reactions in the US. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns about

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... This is an important milestone for DBV, as we are one step closer towards

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the

  • Aimmune preps EU filing for peanut allergy immunotherapy Aimmune preps EU filing for peanut allergy immunotherapy

    The regulatory timeframe outs Aimmune ahead of French biotech DBV Technologies – which is gearing up to refile its Viaskin Peanut candidate later this year in the US having had to withdraw ... Analysts have also suggested that aside from the

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics